Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock is soaring.
The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.
The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda. This story matters for Finance & Markets readers tracking trade. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. Trade-News curates and briefs the finance & markets stories that matter. Our editorial policy →